An observational study in Asthma (Diagnosis), sponsored by Central Hospital, Nancy, France. Completed at 1 site in France. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Central Hospital, Nancy, France · Observational
Among 296 studies in Asthma with a site in France — 45 open to participants now, 58 under way, 8 of them phase 3. Asthma · France.
Among the 296 studies in Asthma with a site in France, this one is the 55th largest by enrollment of the 92 observational ones, is one of 13 that started in 2024, is one of 92 observational ones, and was the 296th registered.
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's enrollment of 100 is below the median of 158 across 1,250 observational studies indexed under Asthma.
Browse Asthma studies →45 of the 296 studies in Asthma with a site in France are open now, in 12 countries. Each count lists the studies.
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 146 take children under 18; 104 take healthy volunteers.
This study: 5 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →296 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 13 started in 2024.
Median enrollment 212 across the 204 interventional studies, 137 across the 92 observational. Of the 220 that completed or were terminated, 85 (39%) have results posted.
147 of 296 have an industry lead sponsor. The 10 most frequent:
Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.
Central Hospital, Nancy, France has 7 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
11 of the studies in Asthma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT05525169Nantes University HospitalStudy of the Impact of Exposure to Outdoor and Indoor Pollutants in Patients With Asthma | 2026-11-15 |
| NCT06988358University Hospital, RouenEarly Identification of Children With Asthma | 2026-12-31 |
| NCT05734261University Hospital, MontpellierForced Oscillations Technique During a Metacholine Test in Children | 2027-02-06 |
Among the 296 studies in Asthma with a site in France, from their registry updates:
Exertional dyspnea has a significant impact on a child's daily life. Current guidelines recommend performing an exercise challenge test to confirm or rule out exercise-induced bronchoconstriction (EIB). But the test is not widely available. The objective of this research is to identify the clinical and respiratory functional factors predictive of a positive exercise challenge test in children.
Exertional dyspnea is a frequent reason for consultation in pediatric pulmonology. The perception of dyspnea varies from one child to another, with some children over- or under- perceiving its intensity. Dyspnea has a significant impact on a child's daily life and quality of life and, in pediatrics, always raises the suspicion of exercise-induced asthma. Current guidelines recommend performing an exercise challenge test to confirm or rule out exercise-induced bronchoconstriction (EIB) if it is suspected. However, this test is not widely available. The objective of this research is to identify the clinical and respiratory functional factors predictive of a positive exercise challenge test in children.
The potential benefit of this study is to better identify individuals who would benefit from undergoing an exercise challenge test.
Children referred by a pediatric pulmonologist to the pediatric respiratory function testing department in 2024 and 2025 for an exercise test. Children with asthma diagnosed by a physician will be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children with a reduction in FEV1 \< 10% from baseline after the exercise challenge test
Children with a reduction in FEV1 ≥ 10% from baseline after the exercise challenge test
Presence of wheezing at exercise
Presence of reported exercise-induced wheezing, as documented in the subject's electronic medical record (yes/no; binary variable).
Time frame: The test duration (3 hours)
Presence of reported dyspnea at exercise
Presence of reported exercise-induced dyspnea, as documented in the subject's electronic medical record (yes/no; binary variable).
Time frame: The test duration 3 hours
Presence of reported cough at exercise
Presence of reported exercise-induced cough, as documented in the subject's electronic medical record (yes/no; binary variable).
Time frame: The test duration 3 hours
Presence of reported chest tightness at exercise
Presence of reported exercise-induced chest tightness, as documented in the subject's electronic medical record (yes/no; binary variable).
Time frame: The test duration 3 hours
Functional parameters - FEV1 z-score at baseline
Spirometric parameters measured before exercise testing - FEV1 z-score (forced expiratory volume in 1 sec) from spirometry performed before exercise testing and documented in the electronic folder of the patient
Time frame: The test duration 3 hours
Reported atopy
Presence of asthma or atopy history, as documented in the subject's electronic medical record (yes/no; binary variable).
Time frame: The test duration 3 hours
Reported clinical history
Reported early respiratory history (≥ 3 wheezing episodes before the age of 3 years; at least one episode of pneumonia or atelectasis), from the clinical history recorded in the electronic folder of the patients (yes/no, binary variable)
Time frame: The test duration 3 hours
Functional parameters - FEV1/FVC z-score at baseline
Spirometric parameters measured before exercise testing - FEV1/FVC z-score (FVC = forced vital capacity) from spirometry performed before exercise testing and documented in the electronic folder of the patient
Time frame: The test duration 3 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Jun 2026, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →